Hillhurst Biopharmaceuticals

Hillhurst Biopharmaceuticals is a clinical‑stage biopharmaceutical company developing liquid formulations of therapeutic gases using its GLASS platform. Lead candidate HBI-002, an oral low‑dose carbon monoxide therapy, completed a successful Phase 1 safety and oral delivery trial in healthy volunteers in 2023 and is in Phase 2a studies for sickle cell disease and Parkinson’s disease, supported by NIH SBIR funding[2][4]. HBI-201, an oral nitrous oxide therapy for acute pain, has NIH HEAL Initiative support and is in preclinical/early clinical development[2][6][9]. HBI-137 is an intravenous low‑dose carbon monoxide product in development for kidney transplant surgery to prevent delayed graft function[2].